BioSpace News Archive

Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on March 22, 2018, the Compensation Committee of the Board of Directors approved “inducement” grants to 7 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia.

Eisai Co., Ltd. announced that in the 8th meeting of the Data Safety Monitoring Board for the global Phase III clinical studies on the investigational oral BACE inhibitor elenbecestat in early Alzheimer’s disease, the DSMB reviewed safety data including the potential for decline in cognition, and recommended the continuation of the studies.

“RareSeq” is able to detect mutations as rare as 1:10,000

Can-Fite BioPharma Ltd. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission.

Army veteran and Gainesville resident Charles Miller had tried other adaptive sports, but not jiu jitsu.

Arkansas Mission of Mercy to provide two-day free dental clinic in Springdale, AR

Dr. Cap Lesesne of International Cosmetic Surgery in New York City announces a new body contouring treatment combining ultrasonic skin tightening technology with power assisted liposuction resulting in the ultimate body sculpting for both men and women.

The American Diabetes Association’s Chief Scientific, Medical and Mission Officer, William T. Cefalu, MD, will testify before the U.S. House of Representatives Committee on Energy & Commerce’s Oversight and Investigations Subcommittee

GENFIT SA (Euronext: GNFT – ISIN: FR0004163111) (“GENFIT” or the “Company”), a French biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, today announced the closing of its previously announced global offering to specified categories of investors of an aggregate of 7,647,500 new ordinary shares